Pembrolizumab Provides First-Ever Overall Survival Improvement in Kidney Cancer

https://www.cancer.gov/news-events/cancer-currents-blog/2024/kidney-cancer-pembrolizumab-increases-survival?cid=eb_govdel The immunotherapy drug pembrolizumab (Keytruda) has rapidly become one of the most widely used cancer treatments. Based on updated results from a large clinical trial, the drug is now part of an important milestone in the treatment of kidney cancer—specifically, clear-cell renal cell carcinoma, the most common form of the disease.